Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Allakos stock | $107.48

Learn how to easily invest in Allakos stock.

Allakos Inc is a biotechnology business based in the US. Allakos shares (ALLK) are listed on the NASDAQ and all prices are listed in US Dollars. Allakos employs 151 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Allakos

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ALLK – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Allakos stock price (NASDAQ: ALLK)

Use our graph to track the performance of ALLK stocks over time.

Allakos shares at a glance

Information last updated 2021-10-10.
Latest market close$107.48
52-week range$75.41 - $157.98
50-day moving average $100.06
200-day moving average $95.66
Wall St. target price$143.10
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.84

Buy Allakos shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Allakos stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Allakos price performance over time

Historical closes compared with the close of $107.48 from 2021-10-15

1 week (2021-10-07) 4.97%
1 month (2021-09-16) 1.62%
3 months (2021-07-16) 32.99%
6 months (2021-04-16) 2.85%
1 year (2020-10-16) 32.92%
2 years (2019-10-16) 50.68%
3 years (2018-10-16) 187.38%
5 years (2016-10-12) N/A

Allakos financials

Gross profit TTM $0
Return on assets TTM -22.09%
Return on equity TTM -39.12%
Profit margin 0%
Book value $10.59
Market capitalisation $5.6 billion

TTM: trailing 12 months

Shorting Allakos shares

There are currently 2.9 million Allakos shares held short by investors – that's known as Allakos's "short interest". This figure is 11.6% down from 3.3 million last month.

There are a few different ways that this level of interest in shorting Allakos shares can be evaluated.

Allakos's "short interest ratio" (SIR)

Allakos's "short interest ratio" (SIR) is the quantity of Allakos shares currently shorted divided by the average quantity of Allakos shares traded daily (recently around 225013.86522076). Allakos's SIR currently stands at 12.91. In other words for every 100,000 Allakos shares traded daily on the market, roughly 12910 shares are currently held short.

However Allakos's short interest can also be evaluated against the total number of Allakos shares, or, against the total number of tradable Allakos shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Allakos's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Allakos shares in existence, roughly 50 shares are currently held short) or 0.0784% of the tradable shares (for every 100,000 tradable Allakos shares, roughly 78 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Allakos.

Find out more about how you can short Allakos stock.

Allakos share dividends

We're not expecting Allakos to pay a dividend over the next 12 months.

Allakos share price volatility

Over the last 12 months, Allakos's shares have ranged in value from as little as $75.41 up to $157.98. A popular way to gauge a stock's volatility is its "beta".

ALLK.US volatility(beta: 0.77)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Allakos's is 0.7739. This would suggest that Allakos's shares are less volatile than average (for this exchange).

Allakos overview

Allakos Inc. operates as a clinical stage biopharmaceutical company. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic esophagitis. The is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. Allakos Inc. was incorporated in 2012 and is headquartered in Redwood City, California. .

Frequently asked questions

What percentage of Allakos is owned by insiders or institutions?
Currently 6.353% of Allakos shares are held by insiders and 99.727% by institutions.
How many people work for Allakos?
Latest data suggests 151 work at Allakos.
When does the fiscal year end for Allakos?
Allakos's fiscal year ends in December.
Where is Allakos based?
Allakos's address is: 975 Island Drive, Redwood City, CA, United States, 94065
What is Allakos's ISIN number?
Allakos's international securities identification number is: US01671P1003
What is Allakos's CUSIP number?
Allakos's Committee on Uniform Securities Identification Procedures number is: 01671P100

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site